<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029766</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486Australia-03</org_study_id>
    <nct_id>NCT04029766</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 Single Bolus Dose Followed With a 30 Minute Constant Infusion in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1 Study to Investigate a Single Bolus Dose Followed With a 30 Minute Constant Infusion of HSK3486 on the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single center, open-label, single dose escalation study in healthy male&#xD;
      subjects to investigate a bolus dose followed by a 30 minute constant infusion of HSK3486&#xD;
      over two cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2015</start_date>
  <completion_date type="Actual">June 9, 2016</completion_date>
  <primary_completion_date type="Actual">December 14, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by measurement of Adverse Events</measure>
    <time_frame>First dose of study drug on day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified observer's assessment of alertness/sedation（MOAA/S）</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
    <description>Observe the change of modified observer's assessment of alert /sedation during the whole trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index （BIS）</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median effective dose (ED50)</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to plasma peak concentration(Tmax)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (t1/2z) and mean residence time (MRT)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CL)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Anesthesia</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male, aged 18 - 49 years (inclusive);&#xD;
&#xD;
          -  2. Be in general good health without clinically significant medical history;&#xD;
&#xD;
          -  3. American Society of Anesthesiologists (ASA) Physical Status Classification of I or&#xD;
             II;&#xD;
&#xD;
          -  4. Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive);&#xD;
&#xD;
          -  5. Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen (HBs-Ag),&#xD;
             hepatitis C (HCVAb) and Human Immunodeficiency Virus (HIV) at Screening; and drugs of&#xD;
             abuse, alcohol pre dose on Day -1&#xD;
&#xD;
          -  6. Normal or non-clinically significant findings on a physical examination, 12-lead&#xD;
             electrocardiogram (ECG) and vital signs (respiration rate between 12 and 20 breaths&#xD;
             per minute, blood pressure (BP) between 100-140/60-90 mmHg, heart rate between 50-99&#xD;
             beats per minute, temperature between 35.8°C and 37.5°C and pulse oximetry values &gt;&#xD;
             95% on room air.);&#xD;
&#xD;
          -  7. Clinical laboratory values within the normal limits as defined by the clinical&#xD;
             laboratory, unless the Investigator decided that out-of-range values were not&#xD;
             clinically significant;&#xD;
&#xD;
          -  8. Ability to provide written informed consent;&#xD;
&#xD;
          -  9. Willing and able to follow study instructions and likely to complete all study&#xD;
             requirements;&#xD;
&#xD;
          -  10. Suitable venous and arterial access.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of allergy or sensitivity to: propofol, components of Fresofol 1% MCT/LCT&#xD;
             propofol, or HSK3486 (excipients soy bean oil, glycerine, triglycerides, purified egg&#xD;
             phospholipids, sodium oleate and sodium hydroxide), or plain lignocaine;&#xD;
&#xD;
          -  2. History of clinically significant problems with general anesthesia;&#xD;
&#xD;
          -  3. Current smoker, or a history of regular (more than weekly) use of tobacco- or&#xD;
             nicotine-containing products within 2 months prior to Screening;&#xD;
&#xD;
          -  4. History of excessive alcohol intake (more than four standard drinks daily, on&#xD;
             average) or use of recreational drugs within the last 3 months;&#xD;
&#xD;
          -  5. Use of prescription or over the counter medications within 7 days of&#xD;
             Investigational Product administration, with the exception of contraceptive&#xD;
             medications, paracetamol, oral non-steroidal antiinflammatory agents, topical over the&#xD;
             counter preparations and routine vitamins (if they do not exceed an intake of 20 to&#xD;
             600 times the recommended daily dose), unless agreed as non-clinically relevant by the&#xD;
             Principal Investigator and Sponsor;&#xD;
&#xD;
          -  6. Standard donation of blood within 30 days of the study;&#xD;
&#xD;
          -  7. Donation of plasma or participation in a plasmapheresis program within 7 days&#xD;
             preceding this study;&#xD;
&#xD;
          -  8. Receipt of any investigational study drug within 30 days prior to Screening;&#xD;
&#xD;
          -  9. Unable to fast for the 6 hours prior to Investigational Product administration;&#xD;
&#xD;
          -  10. Clinically significant (as judged by the Investigator) presence of acute illness&#xD;
             (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract&#xD;
             infection) at admission to the clinical study unit;&#xD;
&#xD;
          -  11. Anticipated need for surgery or hospitalization during the study;&#xD;
&#xD;
          -  12. Anatomical abnormality that would potentially interfere with airway management&#xD;
             under unconscious sedation or anesthesia;&#xD;
&#xD;
          -  13. History of posture-related gastric reflux more than twice weekly;&#xD;
&#xD;
          -  14. History of seizures or epilepsy ;&#xD;
&#xD;
          -  15. History of ischaemic heart disease;&#xD;
&#xD;
          -  16. History of brady- or tachy-dysrhythmias requiring medical care;&#xD;
&#xD;
          -  17. History of asthma, with bronchospasm requiring treatment in the last 3 months;&#xD;
&#xD;
          -  18. Any condition, which in the Investigator's opinion, put the subject at significant&#xD;
             risk, could confound the study results or may interfere significantly with the&#xD;
             subject's participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

